The BBC on 11th April reported that shares in Indivior plunged 71% after the US DoJ charged it with fraudulent marketing. A federal grand jury accused Indivior of a “truly shameful scheme to put profits over the health and well-being of patients”. It alleged the firm conducted an illicit scheme to increase sales of Suboxone Film, an opioid drug used to treat opioid addiction. Indivior has issued a rebuttal contesting the charges. The DoJ has demanded at least $3 billion in fines. According to the indictment, Indivior “obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers and health care benefit programmes into believing that Suboxone Film was safer, less divertible, and less abusable than other opioid-addiction treatment drugs” and “lacked any scientific evidence to support those claims”.